What’s Next in Pharmaceutical R&D? A Conversation with Upperton’s Director of Pharmaceutical Sciences
We speak to Upperton’s Director of Pharmaceutical Sciences, Laura Mason, about the upcoming trends she sees emerging in the R&D lab.
We speak to Upperton’s Director of Pharmaceutical Sciences, Laura Mason, about the upcoming trends she sees emerging in the R&D lab.
A one-site CDMO is where GMP, R&D and manufacturing all operate on one site, making the movement of projects streamlined.
Tech transfer in oral solid dose (OSD) manufacturing is one of the most critical, and often underestimated, phases in the drug development lifecycle. For CDMOs, it’s a moment where scientific precision meets operational discipline.
Upperton announces its recognition as winner of the Small Molecule Dosage Form category at the inaugural European CDMO Leadership Awards.
Upperton has increased its filling capability with the installation of the Fill2Weight gravimetric powder filling machine from 3P innovation
By using our framework , sponsors can identify partners who don’t just deliver projects, but build relationships that last.
What exactly is the difference between a CDMO, a CRO, and a CMO? Each plays a vital role in the life sciences ecosystem.
Upperton Pharma have raised over £4,000 for Rainbows, the children’s hospice serving families in Loughborough and across the East Midlands.
The nose to brain pathway can be leveraged to unlock new therapeutic possibilities. Learn about the opportunities of N2B delivery.
CPHI Frankfurt is one of the most anticipated events in the pharmaceutical calendar. Upperton is proud to be exhibiting.